The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023

The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 published by Visiongain in June, 2008. This report consists of 90 pages and the price starts from US $ 2331.

Introduction

Abstract

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.

In particular, this report concentrates on the following essential aspects of the global OTC industry:

• Major therapeutic areas treated by OTC products
• Key industrial players in the OTC market
• Financial forecasts covering the period 2008-2023, including leading brands, countries and therapeutic areas
• Geographical breakdown of the market
• Sales of the highest-selling OTC brands and other relevant information
• Coverage of prescription-only to OTC switching in the pharma industry

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the OTC industry from 2008-2023, including sales by therapeutic area and country
• To discover predicted revenues, growth rates and other key metrics for OTC pharmaceuticals from 2008-2023, including those of leading brands
• To discover possible future OTC switching candidates
• To determine the forces that influence the OTC market:
• Drivers and restraints on market
• Competition
• Strengths, weaknesses, opportunities and threats

Visiongain forecasts that OTC pharmaceutical sales will almost double from 2007 levels by 2023. In the period 2008-2023, the worldwide OTC market will undergo a period of dynamic change. Increasingly aging populations and rising incidence of lifestyle diseases, as well as the need to reduce healthcare costs, will open up new therapeutic areas for OTC switching. Likewise, sales of existing OTC products will rise. At the same time, changes in retail patterns and new ways of advertising will open up access to OTC drugs to a public better educated and more interested in self-medication than at any previous time. Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Consequently, the commercial prospects are very good for companies well placed to serve those growing needs. In these difficult times for the global pharmaceutical industry, OTC sales will become increasingly important, visiongain concludes.

Further unique benefits to you when you order this report:

• You can access your report online, wherever you are
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Table of Contents

1 Executive Summary

2 Introduction to OTC Pharmaceuticals

• 2.1 Over-the-Counter or Behind-the-Counter: What are OTC Pharmaceuticals?
• 2.2 Key Features of OTC Pharmaceuticals
• 2.3 OTC Switching
• 2.4 Manufacture and Distribution of OTC Pharmaceuticals
• 2.5 Regulation of OTC Pharmaceuticals
  • 2.5.1 United States
  • 2.5.2 Japan
  • 2.5.3 European Union
  • 2.5.4 Other Countries
• 2.6 Major Therapeutic Areas for OTC Pharmaceuticals
  • 2.6.1 Analgesics
    • 2.6.1.1 Internal Analgesics
    • 2.6.1.2 External Analgesics
  • 2.6.2 Cough, Cold, and Allergy Products
  • 2.6.3 Gastrointestinal Products
  • 2.6.4 Medicated Skincare Products
    • 2.6.4.1 Minor Cuts and Wounds
    • 2.6.4.2 Acne
    • 2.6.4.3 Rashes, Itchy Skin, Dermatitis and Eczema
    • 2.6.4.4 Cold Sores
    • 2.6.4.5 Warts
    • 2.6.4.6 Fungal Skin Infections
    • 2.6.4.7 Haemorrhoids
    • 2.6.4.8 Other Medicated Skincare Products
  • 2.6.5 Vitamins, Minerals & Supplements
  • 2.6.6 Other OTC Pharmaceuticals

3 The Global OTC Pharmaceutical Market

• 3.1 The World Market for OTC Pharmaceuticals Will Almost Double in Size by 2023
• 3.2 Which are the Largest OTC Therapeutic Categories?
• 3.3 The Leading Global OTC Pharmaceutical Manufacturers
  • 3.3.1 Johnson & Johnson
  • 3.3.2 Bayer
  • 3.3.3 GSK
  • 3.3.4 Novartis
  • 3.3.5 Wyeth
• 3.4 The Leading World OTC Brands
  • 3.4.1 Tylenol is the Only Global Billion Dollar OTC Brand
  • 3.4.2 Claritin Will Loose Its Dominant OTC Market Position
  • 3.4.3 Prilosec OTC Will Face Competition from Generics and New OTC Switches
• 3.5 The OTC Market is Rapidly Changing

4 SWOT Analysis of the OTC Pharmaceutical Industry

• 4.1 SWOT Chart
• 4.2 OTC Switching
• 4.3 Changing World Demographics
• 4.4 Developments in Wholesale and Retail Channels
• 4.5 Brand Identity and Private Labels
• 4.6 Will OTC Move Behind-the-Counter?
• 4.7 New Advertising Opportunities
• 4.8 Safety Concerns Over Misuse and Abuse of OTC Pharmaceuticals

5 The OTC Pharmaceutical Market by Geographical Area

• 5.1 The World OTC Market: China and India Will Increase Their Market Share
• 5.2 The US OTC Market
  • 5.2.1 The US OTC market in 2007
  • 5.2.2 The US OTC Market 2008-2013
• 5.3 The Japanese OTC Market
  • 5.3.1 The Japanese OTC Market in 2007
  • 5.3.2 Leading Japanese OTC Pharmaceutical Companies
    • 5.3.2.1 Taisho
    • 5.3.2.2 Takeda
    • 5.3.2.3 Daiichi Sankyo
    • 5.3.2.4 Lion
  • 5.3.3 The Japanese OTC Market 2008-2013
• 5.4 The European OTC Market
  • 5.4.1 The European OTC Market in 2007
  • 5.4.2 The European OTC market 2008-2013

6 Prescription-Only to OTC Switching

• 6.1 Recent Switching Activity
• 6.2 Gastrointestinal OTC Switching
• 6.3 Cough, Cold and Allergy OTC Switching
• 6.4 Analgesic OTC Switching
• 6.5 Medicated Skincare OTC Switching
• 6.6 Cholesterol-Lowering OTC Switching
• 6.7 Erectile Dysfunction OTC Switching
• 6.8 OTC Switching: A Continuing Trend in 2008-2023

7 Conclusions

List of Tables

• Table 3.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2006-2023
• Table 3.2 World Sales ($bn) for OTC Pharmaceuticals by Therapeutic Class 2007
• Table 3.3 World OTC Sales Forecast ($bn) by Therapeutic Category 2006-2023
• Table 3.4 Sales ($bn) of Top Five World OTC Manufacturing Companies 2007
• Table 3.5 Tylenol Worldwide Sales Forecast ($bn) 2007-2023
• Table 3.6 Claritin (OTC) Worldwide Sales Forecast ($bn) 2007-2023
• Table 3.7 Prilosec OTC Worldwide Sales Forecast ($bn) 2007-2023
• Table 4.1 SWOT Chart for the OTC Pharmaceutical Industry
• Table 4.2 World Population 2007-2023
• Table 4.3 China, India, US & Japan Population 2007-2023
• Table 4.4 GDP ($tr) US, Japan, China & India 2007-2023
• Table 5.1 OTC Pharmaceutical Sales by Country 2007
• Table 5.2 OTC Share of Pharma Market by Country 2007
• Table 5.3 Forecast World Sales ($bn) of OTC Pharmaceuticals by Country 2007-2023
• Table 5.4 OTC Therapeutic Areas US 2007
• Table 5.5 Largest selling OTC Pharmaceutical Brands in the US 2007
• Table 5.6 Sales ($m) of alli in the US 2007-2013
• Table 5.7 OTC Therapeutic Areas in Japan 2006
• Table 5.8 Leading Japanese OTC Manufacturing Companies 2006-07
• Table 5.9 Leading Cough, Cold and Allergy Brands in Japan 2008-2013
• Table 5.10 Sample European OTC Country Markets 2007
• Table 5.11 OTC Therapeutic Areas in Europe 2007
• Table 6.1 Selected Recent Prescription-Only to OTC Switches
• Table 6.2 Selected Possible Future OTC Switches
• Table 7.1 Leading OTC Country Markets 2007 & 2023

List of Figures

• Figure 1.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2007-2023
• Figure 2.1 The OTC Pharmaceutical Supply Chain
• Figure 3.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2007-2023
• Figure 3.2 World Sales Forecast ($bn) for Pharmaceuticals 2007-2023
• Figure 3.3 World OTC Sales Forecast ($bn) by Therapeutic Category 2007-2023
• Figure 3.4 Share of World OTC Pharmaceutical Sales by Therapeutic Category 2007
• Figure 3.5 Forecast Share of World OTC Sales by Therapeutic Category 2013
• Figure 3.6 Forecast Share of World OTC Sales by Therapeutic Category 2018
• Figure 3.7 Forecast Share of World OTC Sales by Therapeutic Category 2023
• Figure 3.8 Sales ($bn) of Top Five World OTC Manufacturing Companies 2007
• Figure 3.9 Tylenol, Prilosec OTC and Claritin (OTC) World Sales Forecast 2007-2023
• Figure 4.1 Populations of US, Japan, China and India 2007-2023
• Figure 4.2 Population Aged 65 or Over in US, Japan, China and India 2007-2023
• Figure 4.3 Populations % Aged 65 or Over in US, Japan, China and India 2007-2023
• Figure 4.4 Gross Domestic Product ($tr) for US, Japan, China and India 2007-2023
• Figure 5.1 Forecast Sales ($bn) of OTC Pharmaceuticals by Country 2007-2023
• Figure 5.2 Forecast Sales ($bn) of OTC Pharmaceutical by Country 2007-2023
• Figure 5.3 Market Share of World OTC Pharmaceutical Sales by Country 2007
• Figure 5.4 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2013
• Figure 5.5 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2018
• Figure 5.6 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2023
• Figure 5.7 Sales ($m) of alli in the US 2007-2013
• Figure 5.8 Leading Japanese OTC Pharmaceutical Companies 2006-07
• Figure 5.9 Leading Cough, Cold and Allergy Brands in Japan 2008-2013

Organisations Mentioned in this Report

• AmerisourceBergen
• Abbott Laboratories
• Adams Respiratory
• Alliance Boots
• AstraZeneca
• Barr
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cardinal Health
• Celesio
• Chattem
• CNS
• Daiichi Sankyo
• Dr.Reddy' s
• Eisai
• European Medicines Agency (EMEA)
• Food and Drug Administration (FDA)
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Kowa
• Lion
• McKesson
• Medicines and Healthcare products Regulatory Agency (MHRA) (formerly MCA, (Medicines Control Agency))
• Menarini
• Merck & Co.
• Ministry of Health, Labour and Welfare (MHLW)
• Mission Pharmacal
• Novartis
• Perrigo
• Pfizer
• Phoenix Group
• Proctor & Gamble
• Ranbaxy
• Reckitt Benckiser
• Roche
• Rohto
• Sanofi-Aventis
• Santarus
• Sato
• Schering-Plough
• SSP
• Taisho
• Takeda
• TAP
• Target
• Teva
• Wal-Mart Stores
• Wyeth
• Zepharma

Related Reports